Top Markets
Coin of the day
CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY
Rangering i aksjer #6080
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Aksjekurs
$32.48
Sist synkronisert: 2024-03-25
Markedsverdi
$2.24B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel CymaBay Therapeutics, Inc. (CBAY)

Kategori

Aksjeprishistorikk for CymaBay Therapeutics, Inc. (CBAY)
Høyeste sluttskurs: $32.39 den 2024-03-01

Laveste sluttskurs: $9.00 den 2014-02-01
Aksjeprishistorikk for CymaBay Therapeutics, Inc. fra 2014 til 2026
Årlig aksjeprisytelse
År Ytelse
2024 47.52%
2023 374.76%
2022 35.77%
2021 -49.78%
2020 272.39%
2019 -77.25%
2018 -6.63%
2017 374.80%
2016 15.85%
2015 -81.43%
2014 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$548.88 41.07%
US
$1.06K 49.71%
NL
$122.63 -12.65%
AU
$140.94 461.51%
US
$765.25 7.19%
CH